Want to see GB:RUA full AI Analyst Report?
RUA Life Sciences (RUA) AI Stock Analysis
Top Page
RUA Life Sciences
(LSE:RUA)
The score is held back primarily by weak financial performance quality—ongoing operating losses and continued negative operating/free cash flow—despite improving results and a low-leverage balance sheet. Technical trends are supportive (price above major moving averages and positive MACD), but valuation remains challenged given negative earnings and no dividend data.
RUA Life Sciences (RUA) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 17.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 139.12K
- Price to Earnings (P/E)
- -123.9
- Beta (1Y)
- 0.09
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 59
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
RUA Life Sciences Business Overview & Revenue Model
Company Description
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's ope...
How the Company Makes Money
RUA Life Sciences generates revenue primarily by supplying biomaterials and related services to medical device companies and other healthcare manufacturers. Key revenue streams include: (1) Biomaterials sales: selling proprietary or specialized medic...
RUA Life Sciences Financial Statement Overview
Summary
Revenue growth and strong gross margin (~69% in 2026) are positives, and the balance sheet is conservatively levered (debt-to-equity ~0.11). However, operating profitability is not yet established (negative EBIT margin ~-18.5%) and cash generation remains weak with negative operating and free cash flow in 2026, which materially constrains the score.
Income Statement
44NeutralBalance Sheet
78PositiveCash Flow
34Negative| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.46M | 4.11M | 2.19M | 2.18M | 1.63M | 1.53M |
| Gross Profit | 3.06M | 3.17M | 1.72M | 1.43M | 1.04M | 980.00K |
| EBITDA | -383.33K | 401.00K | -1.57M | -1.95M | -2.04M | -1.28M |
| Net Income | -145.33K | 1,000 | -1.44M | -2.00M | -2.07M | -1.45M |
Balance Sheet | ||||||
| Total Assets | 9.12M | 9.26M | 8.17M | 5.66M | 7.63M | 10.15M |
| Cash, Cash Equivalents and Short-Term Investments | 3.25M | 3.57M | 3.93M | 1.48M | 2.96M | 6.29M |
| Total Debt | 794.00K | 1.03M | 389.00K | 475.00K | 344.00K | 410.00K |
| Total Liabilities | 1.89M | 1.86M | 987.00K | 980.00K | 1.04M | 1.65M |
| Stockholders Equity | 7.14M | 7.30M | 7.18M | 4.68M | 6.58M | 8.51M |
Cash Flow | ||||||
| Free Cash Flow | -298.00K | -281.00K | -1.38M | -1.62M | -3.27M | -2.04M |
| Operating Cash Flow | -137.00K | -219.00K | -1.33M | -1.17M | -2.36M | -1.42M |
| Investing Cash Flow | -59.00K | 70.00K | -85.00K | -449.00K | -904.00K | -943.00K |
| Financing Cash Flow | -459.00K | -196.00K | 3.89M | 132.00K | -66.00K | 6.68M |
RUA Life Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Positive. The current price of 28.50 is above the 20-day moving average (MA) of 28.18, above the 50-day MA of 28.02, and above the 200-day MA of 20.85, indicating a bullish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 60.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:RUA.
RUA Life Sciences Peers Comparison
Overall Rating
- GB:RUA56Neutral
GB:GDR49Neutral
GB:IHC48.35Neutral
GB:SUN43.6Neutral
GB:CREO43Neutral
GB:OPTI41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:RUA | 56Neutral | GBP 17.69M | -123.91 | -2.03% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:IHC | 48Neutral | GBP 15.47M | -25.37 | -3.85% | ― | 0.88% | 94.67% |
| GB:SUN | 44Neutral | GBP 3.73M | -4.00 | -15.47% | ― | -3.68% | 20.00% |
| GB:CREO | 43Neutral | GBP 51.09M | -2.51 | -38.29% | ― | ― | ― |
| GB:OPTI | 41Neutral | GBP 5.99M | -1.40 | -77.85% | ― | 11.90% | -2864.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:RUA | Rua Life Sciences Plc | 28.50 | 16.50 | 137.50% | |
| GB:CREO | Creo Medical | 11.38 | 0.13 | 1.11% | |
| GB:GDR | Genedrive plc | 0.97 | 0.01 | 1.25% | |
| GB:IHC | Inspiration Healthcare | 17.25 | -3.00 | -14.81% | |
| GB:OPTI | OptiBiotix Health | 5.80 | -2.20 | -27.50% | |
| GB:SUN | Surgical Innovations Group Plc | 0.40 | -0.18 | -31.03% |
RUA Life Sciences Corporate Events
RUA Life Sciences Narrows Losses as Core Manufacturing Turns Profitable and Spin-Out Strategy Takes Shape
PositiveRUA Life Sciences reported interim results for the six months to 31 March 2026 showing a sharp narrowing of losses as it consolidates its shift toward profitable contract manufacturing and biomaterials licensing. Group revenue rose 6.1% to £2.75...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026